Effect of Hic-5 gene knockout on NF-κB/p65 expression and CCl4-induced liver fibrosis degree in mice

Yang DaYin; Du YiChao; Tan Peng; Chen Hao; Qian BaoLin; Wang AnKang; Huang ShiYao; Fu WenGuang; Xia XianMing

doi:10.3969/j.issn.1001-5256.2019.11.019

Volume 35 Issue 11

Nov. 2019

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2019 > 35(11): 2483-2488

PDF( 2590 KB)

Effect of Hic-5 gene knockout on NF-κB/p65 expression and CCl4-induced liver fibrosis degree in mice

DOI: 10.3969/j.issn.1001-5256.2019.11.019

Department of Hepatobiliary Surgery,The Affiliated Hospital of Southwest Medical University

Research funding:

Received Date: 2019-07-10
Published Date: 2019-11-20

Abstract

Abstract

Objective To investigate the effect of Hic-5 gene knockout on NF-κB/p65 expression and liver fibrosis. Methods Ten wild-type male C57 BL/6 mice were randomly divided into wild-type control group( WT-Control group with 5 mice) and wild-type experimental group( WT-CCl4 group with 5 mice),and ten male C57 BL/6 mice with Hic-5 gene knockout were randomly divided into Hic-5 knockout control group( Hic-5 KO-Control group with 5 mice) and Hic-5 knockout experimental group( Hic-5 KO-CCl4 group with5 mice). The serum levels of alanine aminotransferase( ALT) and aspartate aminotransferase( AST) were measured. Picrosirius red staining was used to observe collagen deposition in liver tissue. Immunohistochemistry was used to measure the expression of alpha-smooth muscle actin( α-SMA) and p65 protein,and real-time quantitative PCR was used to measure the mRNA expression of α-SMA,collagen1,and p65 in liver tissue. The primary hepatic stellate cells of mice were isolated and stimulated with different concentrations of TGF-β1,and then real-time quantitative PCR was used to measure the mRNA expression of α-SMA,collagen 1,and p65 in primary hepatic stellate cells. A one-way analysis of variance was used for comparison of continuous data between multiple groups,and the least significant difference t-test was used for further comparison between two groups. Results Picrosirius red staining showed that compared with the WT-CCl4 group,the Hic-5 KO-CCl4 group had a significant reduction in collagen fibers in liver tissue( P < 0. 001). Measurement of serum ALT and AST showed that there were significant differences in ALT and AST between the WT-Control group,the WT-CCl4 group,the Hic-5 KO-Control group,and the Hic-5 KO-CCl4 group( F = 22. 85 and 25. 15,both P < 0. 001),and the Hic-5 KO-CCl4 group had significantly lower serum levels of ALT and AST than the WT-CCl4 group( both P < 0. 05). Immunohistochemistry showed that there were significant differences in the expression levels of α-SMA and p65 protein in liver tissue between the WT-Control group,the WT-CCl4 group,the Hic-5 KO-Control group,and the Hic-5 KO-CCl4 group( F = 207. 10 and 98. 16,both P < 0. 001),and the Hic-5 KO-CCl4 group had significantly lower expression of α-SMA and p65 protein in liver tissue than the WT-CCl4 group( both P < 0. 01).The results of real-time quantitative PCR showed that there were significant differences in the relative mR NA expression of α-SMA,collagen 1,and p65 in liver tissue between the WT-Control group,the WT-CCl4 group,the Hic-5 KO-Control group,and the Hic-5 KO-CCl4 group( F = 41. 62,13. 93,and 98. 16,all P < 0. 001),and the Hic-5 KO-CCl4 group had significantly lower relative mR NA expression of α-SMA,collagen 1,and p65 in liver tissue than the WT-CCl4 group( all P < 0. 05). After the primary hepatic stellate cells were stimulated by TGF-β1 at concentrations of 0,5,and 10 ng/ml,there were significant differences in the relative mR NA expression ofα-SMA,collagen 1,and p65 between the WT 0 ng/ml group,the WT 5 ng/ml group,the WT 10 ng/ml group,the KO 0 ng/ml group,the KO 5 ng/ml group,and the KO 10 ng/ml group( F = 53. 9,75. 82,and 52. 41,all P < 0. 001),and the Hic-5 KO group had significantly lower relative mR NA expression of α-SMA,collagen 1,and p65 than the WT group( all P < 0. 01). Conclusion Hic-5 knockout inhibits NF-κB/p65 expression and hepatic stellate cell activation and alleviates CCl4-induced liver fibrosis.
- liver cirrhosis,
- hepatic stellate cells,
- mice,knockout,
- mice,inbred C57BL

FullText(HTML)

References(29)

References

[1] YANG JJ,TAO H,LI J. Hedgehog signaling pathway as key player in liver fibrosis:New insights and perspectives[J]. Expert Opin Ther Targets,2014,18(9):1-11.

[2] ISMAIL MH,PINZANI M. Reversal of hepatic fibrosis:pathophysiological basis of antifibrotic therapies[J]. Hepat Med,2011,3:69-80.

[3] HIGASHI T,FRIENDMAN SL,HOSHIDA Y. Hepatic stellate cells as key target in liver fibrosis[J]. Adv Drug Deliv Rev,2017,121:27-42.

[4] LI H,LAN J,HAN C,et al. Brg1 promotes liver fibrosis via activation of hepatic stellate cells[J]. Exp Cell Res,2018,364(2):191-197.

[5] WANG Y,WANG R,PENG R,et al. Ginkgo biloba extract mitigates liver fibrosis and apoptosis by regulating p38 MAPK,NF-κB/IκBα，and Bcl-2/Bax signaling[J]. Drug Des Devel Ther,2015,9:6303-6317.

[6] SU FF,JIN HY,QING S,et al. Downregulation of UBC9 promotes apoptosis of activated human LX-2 hepatic stellate cells by suppressing the canonical NF-κB signaling pathway[J]. PLo S One,2017,12(3):e0174374.

[7] LEI XF,FU W,KIM-KANEYAMA JR,et al. Hic-5 deficiency attenuates the activation of hepatic stellate cells and liver fibrosis through upregulation of Smad7 in mice[J]. J Hepatol,2015,64(1):110-117.

[8] MASCHMEYER P,FLACH M,WINAU F. Seven steps to stellate cells[J]. J Vis Exp,2011,51:2710.

[9] ASSELAH T,MARCELLIN P,BEDOSSA P. Improving performance of liver biopsy in fibrosis assessment[J]. J Hepatol,2014,61(2):193-195.

[10] ALMPANIS Z,DEMONAKOU M,TINIAKOS D. Evaluation of liver fibrosis:“Something old,something new…”[J]. Ann Gastroenterol,2016,29(4):445-453.

[11] GBD 2013 Risk Factors Collaborators,FOROUZANFAR MH,ALEXANDER L,et al. Global,regional,and national comparative risk assessment of 79 behavioural,environmental and occupational,and metabolic risks or clusters of risks in 188countries,1990-2013:A systematic analysis for the Global Burden of Disease Study 2013[J]. Lancet, 2015, 386(10010):2287-2323.

[12] TSOCHATZIS EA,BOSCH J,BURROUGHS AK. Liver cirrhosis[J]. Lancet,2014,383(9930):1749-1761.

[13] CAMPANA L,IREDALE JP. Regression of liver fibrosis[J].Semin Liver Dis,2017,37(1):1-10.

[14] JUNG YK,YIM HJ. Reversal of liver cirrhosis:Current evidence and expectations[J]. Korean J Intern Med,2017,32(2):213-228.

[15] LIU W,YU SY,YAN HZ,et al. Therapeutic effect of MSCs transplantation on rats with hepatic fibrosis[J]. Chin J Med Offic,2017,45(9):903-907.(in Chinese)刘卫，余森源，严和中，等．骨髓间质干细胞移植对肝纤维化模型大鼠治疗效果[J]．临床军医杂志，2017,45(9):903-907.

[16] CHEN W,ZHANG Z,YAO Z,et al. Activation of autophagy is required for Oroxylin A to alleviate carbon tetrachloride-induced liver fibrosis and hepatic stellate cell activation[J]. Int Immunopharmacol,2018,56:148-155.

[17] GANDHI,CHANDRASHEKHAR R. Hepatic stellate cell activation and pro-fibrogenic signals[J]. J Hepatol,2017,67(5):1104-1105.

[18] CHRISTIAN T,FRIEDMAN SL,DETLEF S,et al. Hepatic fibrosis:Concept to treatment[J]. J Hepatol,2015,62(1):s15-s24.

[19] ANDREA O,SANKAR G,The NF-kappaB family of transcription factors and its regulation[J]. Cold Spring Harb Perspect Biol,2009,1(4):a000034.

[20] LIU JM,LIU CC,LIU XM,et al. Long term toxicity of chelerythrine on lung tissue of rats and its effect on expression of NF-κB in lung tissue[J]. J Jilin Univ:Med Edit,2019,45(3):518-523.(in Chinese)刘建明，刘宸辰，刘新民，等．白屈菜赤碱对大鼠肺组织的长期毒性作用及其对肺组织中NF-κB表达的影响[J]．吉林大学学报:医学版，2019,45(3):518-523.

[21] WANG R,WANG J,SONG F,et al. Tanshinol ameliorates CCl4-induced liver fibrosis in rats through the regulation of Nrf2/HO-1 and NF-κB/IκBαsignaling pathway[J]. Drug Des Devel Ther,2018,12:1281-1292.

[22] GHOSH G,WANG VY,HUANG DB,et al. NF-κB regulation:Lessons from structures[J]. Immunol Rev,2012,246(1):36-58.

[23] SEKI E,de MINICIS S,CHRISTOPH H,et al. TLR4 enhances TGF-βsignaling and hepatic fibrosis[J]. Nat Med,2007,13(11):1324-1332.

[24] XING H,GUANG BIN P,RUI T,et al. Activation of nuclear factor kappa B in the hepatic stellate cells of mice with schistosomiasis japonica[J]. PLo S One,2014,9(8):e104323.

[25] WANG F,LIU S,DU T,et al. NF-κB inhibition alleviates carbon tetrachloride-induced liver fibrosis via suppression of activated hepatic stellate cells[J]. Exp Ther Med,2014,8(1):95-99.

[26] MCFARLAND BC,HONG SW,RAJBHANDARI R,et al. NF-κB-induced IL-6 ensures STAT3 activation and tumor aggressiveness in glioblastoma[J]. PLo S One, 2013, 8(11):e78728.

[27] POLINA K,MAYA S,IRINA T,et al. Both MAPK and STAT3signal transduction pathways are necessary for IL-6-dependent hepatic stellate cells activation[J]. PLo S One,2017,12(5):e0176173.

[28] FLETCHER NF,CLARK AR,BALFE P,et al. TNF superfamily members promote hepatitis C virus entry via an NF-κB and myosin light chain kinase dependent pathway[J]. J Gen Virol,2017,98(3):405-412.

[29] CHEN G,WANG Y,LI M,et al. Curcumol induces HSC-T6 cell death through suppression of Bcl-2:Involvement of PI3K and NF-κB pathways[J]. Eur J Pharm Sci,2014,65:21-28.

Relative Articles

[1]	Perioperative Management Group, Chinese Society of Organ Transplantation, Chinese Medical Association. Expert consensus on perioperative vascular complications for liver transplantation(2021)[J]. Journal of Clinical Hepatology, 2021, 37(9): 2054-2057. doi: 10.3969/j.issn.1001-5256.2021.09.010
[2]	Wang AiMin, Jiao HaiTao, Fang ChaoRan, Li JianHui. A case of splenic rupture after endoscopic retrograde cholangiopancreatography[J]. Journal of Clinical Hepatology, 2020, 36(6): 1356-1357. doi: 10.3969/j.issn.1001-5256.2020.06.035
[3]	Ma Min, Zhou ZhongYin. A comparative analysis of acute pancreatitis and hyperamylasemia after endoscopic retrograde cholangiopancreatography[J]. Journal of Clinical Hepatology, 2020, 36(2): 395-398. doi: 10.3969/j.issn.1001-5256.2020.02.033
[4]	Ma Min, Zhou ZhongYin. Current status of clinical research on hematobilia[J]. Journal of Clinical Hepatology, 2019, 35(2): 438-440. doi: 10.3969/j.issn.1001-5256.2019.02.044
[5]	Hu Cui, Bao JunJun, Liu XiaoChang, Ding ShaoZhen, Mei Qiao, Xu JianMing. Effect of diclofenac sodium on the level of non-steroidal anti-inflammatory drug-activated gene-1 in patients with post-ERCP pancreatitis[J]. Journal of Clinical Hepatology, 2018, 34(3): 540-543. doi: 10.3969/j.issn.1001-5256.2018.03.018
[6]	Xu Hui, Li Bing. Research advances in endoscopic treatment of biliary complications after liver transplantation[J]. Journal of Clinical Hepatology, 2018, 34(10): 2245-2250. doi: 10.3969/j.issn.1001-5256.2018.10.041
[7]	Chinese Digestive Endoscopist Committee, Chinese Endoscopist Association, Chinese Physicians′Association, Pancreatic Disease Committee, Chinese Physicians′Association. Expert consensus on perioperative medication for endoscopic retrograde cholangiopancreatography[J]. Journal of Clinical Hepatology, 2018, 34(12): 2555-2562. doi: 10.3969/j.issn.1001-5256.2018.12.010
[8]	Zhang WeiFeng, Li JiaSu, Liu Feng, Cheng YiFeng, Shen Peng. Research advances in the prevention and treatment of pancreatitis after endoscopic retrograde cholangiopancreatography[J]. Journal of Clinical Hepatology, 2018, 34(3): 658-662. doi: 10.3969/j.issn.1001-5256.2018.03.049
[9]	Zhu YiZhou, Wang Ying, Zhu Chang, Xu XiaoRong. An excerpt of JSGE clinical practice guideline for post-ERCP pancreatitis (2017)[J]. Journal of Clinical Hepatology, 2017, 33(12): 2283-2287. doi: 10.3969/j.issn.1001-5256.2017.12.005
[10]	Wang ChunQiu, Ma YingCai, Zhu ZhiYong, Yuan Ling. Risk factors for recurrence of common bile duct stones after endoscopic retrograde cholangiopancreatography[J]. Journal of Clinical Hepatology, 2017, 33(2): 297-299. doi: 10.3969/j.issn.1001-5256.2017.02.019
[11]	Wang Ai, Zhao LiJin. Research advances in pharmacological prevention of pancreatitis after endoscopic retrograde cholangiopancreatography[J]. Journal of Clinical Hepatology, 2017, 33(1): 184-187. doi: 10.3969/j.issn.1001-5256.2017.01.043
[12]	Li Lu, Wei HongCheng, Feng ShuFen. Clinical effect of ulinastatin in preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a Meta-analysis[J]. Journal of Clinical Hepatology, 2017, 33(1): 110-115. doi: 10.3969/j.issn.1001-5256.2017.01.024
[13]	Pancreatic Disease Committee of Chinese Medical Doctor Association, Chinese Society of Digestive Endoscopy, Chinese Medical Association. Expert consensus on pharmacological prevention of pancreatitis after endoscopic retrograde cholangiopancreatography (2015, Shanghai)[J]. Journal of Clinical Hepatology, 2016, 32(5): 830-834. doi: 10.3969/j.issn.1001-5256.2016.05.002
[14]	YIERPAN Aishan, Gao Feng. Risk factors for hyperamylasemia after endoscopic retrograde cholangiopancreatography[J]. Journal of Clinical Hepatology, 2016, 32(1): 119-122. doi: 10.3969/j.issn.1001-5256.2016.01.022
[15]	Zhong HengGao, Mou Lin, Ji GuoZhong, Jiang GuoBin, Yang LiHua, Liu Zheng, Fan ZhiNing. Expression of Toll-like receptor 4 in rat model of nonalcoholic fatty liver disease induced by hyperlipidemia[J]. Journal of Clinical Hepatology, 2015, 31(12): 2070-2072. doi: 10.3969/j.issn.1001-5256.2015.12.020
[16]	Bi RongXin, Guo QuanZhou, Xue ZhiGuang, Hou ZhiQiang. Analysis of incidence and risk factors for ERCP-related adverse events in patients with primary sclerosing cholangitis[J]. Journal of Clinical Hepatology, 2015, 31(2): 189-192. doi: 10.3969/j.issn.1001-5256.2015.02.011
[17]	Li XiaoQing, Qian JiaMing. Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline-Updated June 2014[J]. Journal of Clinical Hepatology, 2014, 30(12): 1236-1239. doi: 10.3969/j.issn.1001-5256.2014.12.002
[18]	Zhang RuoYan, Du XiaoHong, Wang Meng, Ye JunFeng, Jin GuoXing, Wang GuangYi. Severe thrombocytopenia in AOSC after ERCP: a report of one case[J]. Journal of Clinical Hepatology, 2014, 30(4): 373-374. doi: 10.3969/j.issn.1001-5256.2014.04.022
[19]	Wang JiHeng, Gao Ge, Shi JiuJian. Causes and countermeasures of delayed hemobilia after endoscopic retrograde cholangiopancreatography[J]. Journal of Clinical Hepatology, 2013, 29(9): 692-694. doi: 10.3969/j.issn.1001-5256.2013.09.015
[20]	He ZhenPing. Large hemobilia caused by a porto-biliary fistula with hepatolithiasis, portal hypertension and poor hepatic function grade: A case report[J]. Journal of Clinical Hepatology, 2012, 28(6): 465-466.

Supplements(0)

Cited By

Cited by

Periodical cited type(8)

1.	范玲，傅燕，刘懿，黄华，倪静，唐娟. 内镜逆行胰胆管造影术后出血的研究进展. 临床肝胆病杂志. 2023(10): 2497-2505 . 本站查看
2.	谭增光，冯树开，王军，冯淑娟. 不同原发疾病行治疗性经内镜逆行胰胆管造影术后胆道出血的风险及防治对策. 中外医学研究. 2020(01): 134-136 .
3.	刘琪，张俊杰. 腹腔镜联合胆道镜下肝内胆管结石钬激光碎石取石术的临床疗效及安全性分析. 哈尔滨医药. 2020(01): 46-47 .
4.	庄伟，郭志娟. 急诊内镜下治疗ERCP乳头切开取石术后迟发性出血10例. 武警医学. 2020(06): 533-534 .
5.	冯树杰，冷凯，贾继虎，曾鹏飞，陈炜，梅永，冯春林. 覆膜支架预防经内镜逆行胰胆管造影术后出血的研究进展. 中国医刊. 2020(07): 709-711 .
6.	马敏，周中银. 胆道出血的临床现状探究. 临床肝胆病杂志. 2019(02): 438-440 . 本站查看
7.	石保平，傅燕，路明亮，刘国彬，李新华，魏莉，胡宜涛，杨娟. 不同内镜下乳头括约肌预切开术在经内镜逆行胰胆管造影术中困难插管时应用的效果比较. 临床肝胆病杂志. 2019(08): 1760-1765 . 本站查看
8.	查育锋，何晓虎，田勉，高军，王刚. 糖链抗原19-9对可切除肝门部胆管癌患者预后及早期复发的预测价值. 临床肝胆病杂志. 2018(05): 1046-1051 . 本站查看

Other cited types(5)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1457) PDF downloads(271)

Effect of Hic-5 gene knockout on NF-κB/p65 expression and CCl4-induced liver fibrosis degree in mice

DOI: 10.3969/j.issn.1001-5256.2019.11.019